Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285146125> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W4285146125 abstract "The persistent use of anticancer medicines can cause multidrug resistance in many tumors and serious cytotoxicity for healthy cells, including adriamycin (ADR), a treatment for breast cancer (BC). Cell resistance to ADR in patients with recurrent advanced BC can occur. Creating effective treatments that can grapple with multidrug resistance is still challenging. Traditional Chinese medicine (TCM) may offer a solution in D Rhamnose beta-hederin (DRβ-H), an oleanane type of triterpenoid saponin.The study intended to assess the ability of DRβ-H to inhibit the ADR resistance of two BC-lineage cell lines, MCF-7 and SUM-1315, and to explore the causal link between DRβ-H and the reversal of chemoresistance.The research team performed a cell biology study.The study took place at laboratory in China.The research team: (1) assessed cell viability and the migration and invasion the cell lines; (2) investigated the molecular mechanism and identified the downstream targets of DRβ-H, and (3) comprehensively examined the expression pattern, underlying functions, and evident prognostic significance of NAP1L5 in BC by gathering the online information available.DRβ-H can inhibit the viability of the MCF-7/ADR and SUM-1315/ADR cancer cells in a dosage-dependent manner. NAP1L5 might be the main target of DRβ-H in reversing ADR resistance. Its expression decreased in BC cells, and the more advanced the BC was, the lower the NAP1L5 expression was.DRβ-H at nontoxic concentrations was related to ADR resistance in BC through its downstream target NAP1L5. NAP1L5 is potentially a preferable prognostic marker for BC." @default.
- W4285146125 created "2022-07-14" @default.
- W4285146125 creator A5001395097 @default.
- W4285146125 creator A5020877899 @default.
- W4285146125 creator A5029731760 @default.
- W4285146125 creator A5059997582 @default.
- W4285146125 creator A5082975780 @default.
- W4285146125 date "2022-01-01" @default.
- W4285146125 modified "2023-09-28" @default.
- W4285146125 title "D Rhamnose β-Hederin Reverses NAP1l5-Mediated Adriamycin Resistance in Breast Cancer" @default.
- W4285146125 cites W1976795511 @default.
- W4285146125 cites W1977918192 @default.
- W4285146125 cites W1980503801 @default.
- W4285146125 cites W1990148464 @default.
- W4285146125 cites W1996023050 @default.
- W4285146125 cites W1999490101 @default.
- W4285146125 cites W2022267672 @default.
- W4285146125 cites W2030092320 @default.
- W4285146125 cites W2041051519 @default.
- W4285146125 cites W2051621722 @default.
- W4285146125 cites W2083296039 @default.
- W4285146125 cites W2124268018 @default.
- W4285146125 cites W2130363647 @default.
- W4285146125 cites W2133600415 @default.
- W4285146125 cites W2147105278 @default.
- W4285146125 cites W2287258341 @default.
- W4285146125 cites W2412426910 @default.
- W4285146125 cites W2414236267 @default.
- W4285146125 cites W2736730167 @default.
- W4285146125 cites W2770405840 @default.
- W4285146125 cites W2803612258 @default.
- W4285146125 cites W2888109810 @default.
- W4285146125 cites W3024134698 @default.
- W4285146125 doi "https://doi.org/10.2139/ssrn.4115187" @default.
- W4285146125 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36689360" @default.
- W4285146125 hasPublicationYear "2022" @default.
- W4285146125 type Work @default.
- W4285146125 citedByCount "0" @default.
- W4285146125 crossrefType "journal-article" @default.
- W4285146125 hasAuthorship W4285146125A5001395097 @default.
- W4285146125 hasAuthorship W4285146125A5020877899 @default.
- W4285146125 hasAuthorship W4285146125A5029731760 @default.
- W4285146125 hasAuthorship W4285146125A5059997582 @default.
- W4285146125 hasAuthorship W4285146125A5082975780 @default.
- W4285146125 hasConcept C114851261 @default.
- W4285146125 hasConcept C121608353 @default.
- W4285146125 hasConcept C126322002 @default.
- W4285146125 hasConcept C133936738 @default.
- W4285146125 hasConcept C2778707650 @default.
- W4285146125 hasConcept C502942594 @default.
- W4285146125 hasConcept C530470458 @default.
- W4285146125 hasConcept C53227056 @default.
- W4285146125 hasConcept C54355233 @default.
- W4285146125 hasConcept C71924100 @default.
- W4285146125 hasConcept C81885089 @default.
- W4285146125 hasConcept C86803240 @default.
- W4285146125 hasConcept C98274493 @default.
- W4285146125 hasConceptScore W4285146125C114851261 @default.
- W4285146125 hasConceptScore W4285146125C121608353 @default.
- W4285146125 hasConceptScore W4285146125C126322002 @default.
- W4285146125 hasConceptScore W4285146125C133936738 @default.
- W4285146125 hasConceptScore W4285146125C2778707650 @default.
- W4285146125 hasConceptScore W4285146125C502942594 @default.
- W4285146125 hasConceptScore W4285146125C530470458 @default.
- W4285146125 hasConceptScore W4285146125C53227056 @default.
- W4285146125 hasConceptScore W4285146125C54355233 @default.
- W4285146125 hasConceptScore W4285146125C71924100 @default.
- W4285146125 hasConceptScore W4285146125C81885089 @default.
- W4285146125 hasConceptScore W4285146125C86803240 @default.
- W4285146125 hasConceptScore W4285146125C98274493 @default.
- W4285146125 hasLocation W42851461251 @default.
- W4285146125 hasLocation W42851461252 @default.
- W4285146125 hasOpenAccess W4285146125 @default.
- W4285146125 hasPrimaryLocation W42851461251 @default.
- W4285146125 hasRelatedWork W1963779461 @default.
- W4285146125 hasRelatedWork W1980169150 @default.
- W4285146125 hasRelatedWork W1990431159 @default.
- W4285146125 hasRelatedWork W2012131086 @default.
- W4285146125 hasRelatedWork W2094731459 @default.
- W4285146125 hasRelatedWork W2355405292 @default.
- W4285146125 hasRelatedWork W2403269861 @default.
- W4285146125 hasRelatedWork W2565040996 @default.
- W4285146125 hasRelatedWork W4211230861 @default.
- W4285146125 hasRelatedWork W771259007 @default.
- W4285146125 isParatext "false" @default.
- W4285146125 isRetracted "false" @default.
- W4285146125 workType "article" @default.